Sutro Biopharma Total Liabilities
Sutro Biopharma total liabilities. Based on the latest financial reports, Sutro Biopharma (STRO) has total liabilities worth $297.78 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check STRO financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sutro Biopharma (2016–2025)
Total liabilities of Sutro Biopharma from 2016 to 2025. This chart illustrates how Sutro Biopharma's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Sutro Biopharma's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Sutro Biopharma Competitors by Total Liabilities
The table below lists competitors of Sutro Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PHX Minerals Inc
NYSE:PHX
|
USA | $35.54 Million |
|
Thai Rayon Public Company Limited
BK:TR
|
Thailand | ฿6.98 Billion |
|
Tantalus Systems Holding Inc
TO:GRID
|
Canada | CA$29.24 Million |
|
Intops Co. Ltd
KQ:049070
|
Korea | ₩121.40 Billion |
|
Wallbridge Mining Company Limited
TO:WM
|
Canada | CA$36.05 Million |
|
Daehan Steel
KO:084010
|
Korea | ₩380.16 Billion |
|
AB Klaipedos nafta
F:XIC
|
Germany | €382.37 Million |
|
WEST RED LAKE GOLD MINES
F:UJ0
|
Germany | €176.71 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Sutro Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see STRO total asset value.
Liquidity & Leverage Metrics
Sutro Biopharma Total Liabilities Ratios Explained
Sutro Biopharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sutro Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sutro Biopharma (2016–2025)
The table below shows the annual total liabilities of Sutro Biopharma from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $306.28 Million | -10.60% |
| 2024-12-31 | $342.61 Million | +6.70% |
| 2023-12-31 | $321.09 Million | +69.09% |
| 2022-12-31 | $189.90 Million | +113.74% |
| 2021-12-31 | $88.84 Million | +43.15% |
| 2020-12-31 | $62.06 Million | +5.94% |
| 2019-12-31 | $58.58 Million | -36.05% |
| 2018-12-31 | $91.60 Million | -38.84% |
| 2017-12-31 | $149.77 Million | -6.50% |
| 2016-12-31 | $160.18 Million | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid… Read more